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Gerhard Pichler11, Gunnar Naulaers12, Guoqiang Cheng13, Hercilia Guimarães14, Jakub Tkaczyk15,
Karen B. Kreutzer16, Monica Fumagalli17,18, Olivier Claris19, Petra Lemmers20, Siv Fredly21, Tomasz Szczapa22,
Topun Austin23, Janus Christian Jakobsen3,24,25 and Gorm Greisen1
Abstract
Background: Cerebral oxygenation monitoring may reduce the risk of death and neurologic complications in
extremely preterm infants, but no such effects have yet been demonstrated in preterm infants in sufficiently
powered randomised clinical trials. The objective of the SafeBoosC III trial is to investigate the benefits and harms of
treatment based on near-infrared spectroscopy (NIRS) monitoring compared with treatment as usual for extremely
preterm infants.
Methods/design: SafeBoosC III is an investigator-initiated, multinational, randomised, pragmatic phase III clinical
trial. Inclusion criteria will be infants born below 28 weeks postmenstrual age and parental informed consent (unless
the site is using ‘opt-out’ or deferred consent). Exclusion criteria will be no parental informed consent (or if ‘opt-out’
is used, lack of a record that clinical staff have explained the trial and the ‘opt-out’ consent process to parents and/
or a record of the parents’ decision to opt-out in the infant’s clinical file); decision not to provide full life support;
and no possibility to initiate cerebral NIRS oximetry within 6 h after birth. Participants will be randomised 1:1 into
either the experimental or control group. Participants in the experimental group will be monitored during the first
72 h of life with a cerebral NIRS oximeter. Cerebral hypoxia will be treated according to an evidence-based
treatment guideline. Participants in the control group will not undergo cerebral oxygenation monitoring and will
receive treatment as usual. Each participant will be followed up at 36 weeks postmenstrual age. The primary
outcome will be a composite of either death or severe brain injury detected on any of the serial cranial ultrasound
scans that are routinely performed in these infants up to 36 weeks postmenstrual age. Severe brain injury will be
assessed by a person blinded to group allocation. To detect a 22% relative risk difference between the experimental
and control group, we intend to randomise a cohort of 1600 infants.
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: mathias.luhr.hansen@gmail.com
1Department of Neonatology, Rigshospitalet, Blegdamsvej 9, 2100
Copenhagen, Denmark
Full list of author information is available at the end of the article
Hansen et al. Trials          (2019) 20:811 
https://doi.org/10.1186/s13063-019-3955-6
(Continued from previous page)
Discussion: Treatment guided by cerebral NIRS oximetry has the potential to decrease the risk of death or survival
with severe brain injury in preterm infants. There is an urgent need to assess the clinical effects of NIRS monitoring
among preterm neonates.
Trial registration: ClinicalTrial.gov, NCT03770741. Registered 10 December 2018.
Keywords: Randomised clinical trial, Preterm, Near infrared spectroscopy, Protocol
Background
Every year, approximately 50,000 extremely preterm in-
fants (< 28 weeks postmenstrual age) are born in coun-
tries where they routinely will be offered neonatal
intensive care [1]. Extremely preterm birth carries a high
risk of death or long-term cerebral impairment. With a
current mortality of about 25% and a prevalence of psy-
chomotor impairment in approximately 20% of survi-
vors, more than 10,000 will die each year and a further
10,000 will suffer from cerebral palsy or moderate-to-
severe cognitive impairment [2–4].
When an infant is born extremely preterm, all organs
are immature and vulnerable [5, 6]. This is particularly
relevant for the immature brain [7]. Cerebral autoregula-
tion is limited and believed to be fragile in extremely
preterm infants [4]. It is hypothesised that large fluctua-
tions in cerebral blood flow may result in cerebral haem-
orrhage arising from immature blood vessels. These
fluctuations in systemic blood flow are common during
the transition from foetal to neonatal circulation during
the first days of life, thus putting the immature brain in
danger [8].
Neonatal brain injury may be diagnosed by cranial
ultrasound [9]. The most severe injuries, including grade
III or IV intraventricular haemorrhage and the non-
haemorrhagic white matter injury cystic periventricular
leukomalacia, entail a high probability of death or cere-
bral palsy [10, 11]. Several pre- and postnatal factors
have been shown or are thought to be associated with
cerebral injury, including ascending infections [12], in-
sufficient nutrition early in life [13], insufficient blood
pressure, cardiac dysfunction, and suboptimal mechan-
ical ventilation [14–16].
Among extremely preterm infants during their first
days of life, current practice standards involve multiple
parallel interventions, including respiratory and haemo-
dynamic support, intravenous fluids, antibiotics, nutri-
tion, and monitoring of physiological parameters.
Despite significant advances in the management of ex-
tremely preterm infants over the past three decades,
many of these interventions are used with little evidence.
Furthermore, an end-organ monitor with sufficient time
resolution to guide evidence-based treatment is lacking.
Near-infrared spectroscopy (NIRS) has the potential to
function in this manner. Cerebral NIRS provides a real-
time continuous estimate of the cerebral tissue oxygen-
ation (rStO2), expressed as a percentage. The normal
ranges of rStO2 in preterm infants have been determined
and change somewhat with gestational age and postnatal
age [17].
The evidence on the utility of NIRS monitoring in ex-
tremely preterm infants during the first days of life is
sparse. Only one previous randomised clinical trial has
assessed the effects of cerebral monitoring—the Safe-
BoosC phase II feasibility trial [18]. This trial showed
that NIRS monitoring reduced the burden of cerebral
hypoxia to less than half compared with treatment as
usual and there were also non-significant trends towards
reduced incidence of severe brain injury and reduced
mortality in the NIRS group [18]. The clinical interven-
tions used in the NIRS-open group included a significant
number with likely beneficial effects on blood oxygen
content and transport, blood pressure, cardiac output,
and cerebral blood flow [19]. Despite these promising re-
sults, it is theoretically possible that NIRS monitoring
may cause harm. This includes skin marks from the sen-
sors, inappropriate modifications in cardio-respiratory
support based on hypoxic values, and unnecessary infant
disturbance due to manipulation of the forehead-based
NIRS sensor. Furthermore, the SafeBoosc II trial showed
a higher prevalence of bronchopulmonary dysplasia and
retinopathy of prematurity in the experimental group.
As NIRS devices and sensors are also costly and moni-
toring confers additional nursing tasks, it would be un-
fortunate to incorporate NIRS monitoring into standard
practice without clear evidence of clinical benefit.
To evaluate the potential benefits and harms of NIRS
monitoring, large-scale randomised clinical trials are ur-
gently warranted. Since the intervention is complex—
NIRS monitoring itself in addition to evidence-based
modification of cardio-vascular support—a pragmatic
design is preferable to ensure relevance for routine neo-
natal intensive care. International participation is add-
itionally necessary to achieve adequate subject numbers
and ideally promote generalisability of the results.
Methods/design
This trial will be conducted in compliance with the
guidelines of The Declaration of Helsinki in its latest
form, the International Conference on Harmonization
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Good Clinical Practice guidelines [20], and applicable
national regulations and directives. No clinical site will
start randomisation before their eligibility has been con-
firmed and the protocol has been approved by the rele-
vant ethics committee. Any amendments to the protocol
will need approval by the Steering Committee and
ethical review before being implemented. Written in-
formed consent will be obtained by a qualified physician
or nurse connected to the trial, prior to randomisation
of any participant, unless the Neonatal Intensive Care
Unit (NICU) uses deferred informed consent or prior
assent as consent methods (see below). These consent
procedures will be approved by local ethics committees
or institutional review boards.
Objective
The objective of this trial is to examine the benefits and
harms of treatment based on NIRS monitoring com-
pared with treatment as usual (standard monitoring and
treatment) to reduce cerebral hypoxia during the first
72 h of life in extremely preterm infants. The hypothesis
is that the application of treatment based on NIRS mon-
itoring will decrease a composite outcome of severe
brain injury or death at 36 weeks postmenstrual age.
Roles and responsibilities for committees
SafeBoosC III is led by a Steering Committee comprising
the coordinating investigator (GG), the national coordi-
nators, and two representatives from the Copenhagen
Trial Unit (CG and JCJ). Decisions will be made by a
simple majority. The executive committee will be re-
sponsible for the day-to-day management and will com-
prise the coordinating investigator, the trial manager
(MLH), co-investigators (AP, GD, JM, SHS), and the two
representatives from the Copenhagen Trial Unit (CG
and JCJ).
There will be one principal investigator in each depart-
ment who will be responsible for obtaining ethical
approval, organising local Good Clinical Practice moni-
toring, informing clinical staff members on the web-
based training and certification program, recruitment of
patients, and data entry into the patient report forms.
The Copenhagen Trial Unit will be responsible for ran-
domisation, development of the patient report forms,
and central monitoring.
Trial design
This is an investigator-initiated, multinational, rando-
mised, pragmatic phase III clinical trial with a two-
parallel group design that will enrol 1600 extremely pre-
term infants from 20 countries (Austria, Belgium, China,
Czech Republic, Denmark, England, France, Germany,
Greece, India, Ireland, Italy, Norway, Poland, Portugal,
Switzerland, Scotland, Spain, Turkey, USA). A list of all
study sites will be available at www.safeboosc.eu. It is an
open label trial, but parts will be conducted blinded to
the intervention (see the ‘Blinding’ section).
The trial has been designed according to the SPIRIT
guidelines (Fig. 1 and Additional file 1) [21].
Inclusion criteria
The inclusion criteria will be infants born before 28
weeks postmenstrual age and signed parental informed
consent unless the NICU has chosen to use ‘opt-out’ or
deferred consent as their consent method.
Exclusion criteria
The exclusion criteria will be no signed parental in-
formed consent (or if the ‘opt-out’ method is used, lack
of a record that the clinical staff have explained the trial
and the ‘opt-out’ consent process to parents and/or a
record of the parents’ decision to opt-out in the infant’s
clinical file); decision not to provide full life support; and
no possibility to initiate cerebral NIRS monitoring
within 6 hours after birth.
Participation in other trials
Participants included in the SafeBoosC III trial can par-
ticipate in any other study or intervention on the condi-
tion that: it does not allow clinical staff access to
cerebral oximetry in the control group from inclusion in
SafeBoosC III to the end of the intervention period 72 h
after birth; and does not exclude a treatment that would
be clearly indicated by the SafeBoosC III evidence-based
treatment guideline during the intervention period. All
partners are encouraged to design ancillary studies and
draw on data collected by SafeBoosC III, if not com-
promising the blinding of assessors or the equipoise of
the trial. Ancillary studies must seek approval by the
SafeBoosC Steering Committee.
Participant discontinuation and withdrawal
A participant’s parents are free to withdraw them from
the SafeBoosC III trial at any time, and this will not have
any consequences for the infant’s further treatment.
Reasons for discontinuation, if provided by the parents,
will be documented. When possible, the parents will be
asked if they will allow their child’s data to be used in
the analysis.
The attending clinician can withdraw the participant
from the trial at any time in case there are safety con-
cerns. Reasons for withdrawal will be documented.
There are no pre-specified criteria for discontinuation of
participants from the trial. Discontinuation of partici-
pants from the trial will not result in replacement with
new participants.
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Recruitment
In this phase III trial, we have prolonged the enrolment
period from 3 hours, as used in SafeBoosC II, to 6 hours
after birth, although we recommend that monitoring is
started as early as possible to help decision-making when
cardio-respiratory support is established. This 6-hour
window is similar to what is currently used for another
neonatal intervention—therapeutic hypothermia for
hypoxic-ischaemic encephalopathy after birth asphyxia
[22]. We believe this will make the trial relevant in
settings where antenatal transfer to a perinatal centre is
used less often, and thereby increase recruitment feasi-
bility without compromising the effect of NIRS
monitoring.
Extremely preterm infants are expected to be included
at about 50 NICUs in about 20 countries. The 93 units
that took part in a previous funding application for the
SafeBoosC III trial had rates of admission of between 15
and 90 extremely preterm infants per year. The total ad-
missions were estimated to be 3000 infants per year. We
should, therefore, have a good chance of recruiting 1600
participants within 2 years. Sites that expect to enrol at
least 15 participants per year within the 2-year recruit-
ment period will take part. Inclusion of new NICUs after
the common start date will be done ad hoc, considering
expected contributions and time remaining.
Randomisation
Infants will be centrally randomised to either the experi-
mental or control group with a 1:1 allocation ratio at the
Copenhagen Trial Unit using a web-based randomisa-
tion application. The allocation sequence will be
computer-generated with varying block sizes concealed
for all investigators, as the web-based program will not
release the randomisation until the patient has been in-
cluded in the trial and stratified by NICU and gestational
age group (lower gestational age (< 26 weeks) compared
to higher gestational age (≥ 26 weeks)). Twin couples will
be randomised to the same group, either intervention or
control. In centres where only one or two NIRS devices
are available, it may not be possible to include all infants
from twin births. Thus, only one of a pair of twins may
be included. The sibling enrolled will be the one born
last.
Blinding
Due to the nature of the experimental intervention, it is
not possible to blind the clinical staff, the infant, or the
parents to study group allocation. Outcome assessment
of mortality will not be blinded but the mortality data
will be checked by Good Clinical Practice via source data
verification in all patients. The diagnosis and classifica-
tion of brain injury along with the entry of these data
Fig. 1 Schedule for enrolment, intervention and assessment, based on the SPIRIT 2013 guidance for protocols of clinical trials. *If approved by the
local ethics committee, deferred informed consent or prior informed assent may be sought. Time to ask parents for deferred consent will be
decided individually by clinical staff members
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into the patient report form will be conducted by an as-
sessor blinded to study group allocation. Data entry pro-
cedures will depend on local factors and will be agreed
on between the principal investigator at each NICU and
the coordinating investigator. The data managers, statis-
ticians, and those drawing conclusions will be blinded to
study group allocation. Details on this is described in a
report on the statistical analysis plan [23].
Intervention
Experimental group participants will undergo cerebral
NIRS monitoring applied as soon as possible after arrival
in the NICU and always within 6 hours after delivery
and receive treatment based on NIRS monitoring during
the first 72 h of life. Treatment will be based on the
same evidence-based guideline as used in the SafeBoosC
II trial (see below) [24].
The control group participants will not receive any cere-
bral NIRS monitoring and will be monitored and treated
according to local guidelines and clinical practices.
Treatment guideline based on NIRS monitoring
An evidence-based treatment guideline recommending
modification of cardio-respiratory support or interven-
tions aiming at increasing blood oxygen transport cap-
acity will be followed in order to maintain cerebral
oxygenation above 55% (Additional file 2) [24]. As the
SafeBoosC II trial showed a low burden of hyperoxia un-
affected by monitoring-based interventions, the Safe-
BoosC III trial will not target cerebral hyperoxia and
therefore the interventions for hyperoxia have been re-
moved from this trial’s treatment guidelines. The same
SafeBoosC III treatment guideline will be used in all
participating centres.
Devices
All commercially available cerebral oximeters that are
approved for clinical use in newborns may be used. The
aim is to use several different devices to generate results
of generic value. There are now seven commercially
available devices that are approved for clinical use in dif-
ferent countries: INVOS (Medtronics, Minneapolis, MN,
USA); NIRO (Hamamatsu, Hamamatsu City, Japan);
Fore-Sight (CAS Medical, Branford, CT, USA); Sensmart
(Nonin Medical, Plymouth, MN, USA); O3 (Masimo, Ir-
vine, CA, USA); Egos (Enginmed, Suzhou, China); and
Oxyprem 1.4 (Oxyprem, Zürich, Switzerland). The nor-
mal range of rStO2 was determined with the INVOS
adult sensor [17] and defined the rStO2 thresholds for
intervention used in the SafeBoosC II trial. Each eligible
device in SafeBoosC III will be compared with the
INVOS adult sensor using a blood lipid phantom and
device-specific thresholds will be determined [25] before
being used in the SafeBoosC III trial.
Training and certification
Clinical staff will be offered a web-based training and
certification program consisting of short modules cover-
ing the trial rationale, NIRS and monitoring of cerebral
oxygenation, the treatment guideline, cerebral ultra-
sound and classification of brain injury, and Good Clin-
ical Practice (www.safeboosc.eu). The use of these
modules and the completion rate will be monitored and
reported with the results of the trial. Sites with low com-
pliance may be selected for subgroup analyses.
Trial duration
NIRS monitoring will start within 6 postnatal hours and
the intervention will last until 72 h of life. Each partici-
pant will be followed up at 36 weeks postmenstrual age.
Explanatory variables
To allow comparisons between intervention groups,
additional baseline clinical data will be obtained, in-
cluding birth weight, gestational age, mechanical venti-
lation, and use of cardiovascular support. Data will be
drawn from clinical records at 72 h of age and 36 weeks
postmenstrual age, the same time as the primary and
exploratory outcomes are assessed and documented.
The majority of these selected variables are usually
reported to neonatal network databases such as the
Vermont Oxford Network [26].
Outcomes
Primary and exploratory outcomes will be assessed at
36 weeks postmenstrual age as documented in the in-
fants’ clinical files. If an infant has been discharged to a
step-down unit, data will be sought from that unit, and
if this is not possible, data will be used until the date of
discharge to the step-down unit. In case the last entry in
an infant’s clinical file is prior to 36 + 0 weeks post-
menstrual age, for example due to discharge home, the
date of discharge will be reported in the online patient
report form.
The primary outcome is a composite of either death
or severe brain injury detected on any one of a series of
cranial ultrasound scans that are routinely performed in
extremely premature infants. Severe brain injury is de-
fined as grade III or IV intraventricular haemorrhage
(IVH), cystic periventricular leukomalacia (cPVL), cere-
bellar haemorrhage, post-haemorrhagic ventricular dila-
tation, or cerebral atrophy. The exploratory outcomes
will be bronchopulmonary dysplasia (BPD), retinopathy
of prematurity (ROP) stage 3+, necrotising enterocolitis
(NEC) stage 2 or higher using the modified Bell’s staging
system and/or focal intestinal perforation, late-onset sep-
sis (> 72 h after birth) defined as being treated with anti-
biotics for a minimum of 5 days, and a count of the
presence of three major neonatal morbidities (BPD,
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ROP, and severe brain injury). All diagnoses, except se-
vere brain injury, are made as per routine in each NICU.
Statistical plan and data analysis
Full details regarding statistical considerations and data
analysis are outlined in a separate report [23], which will
be published before the analysis phase begins, without
knowledge of any data collected.
Sample size
We have calculated our sample size based on the com-
posite primary outcome, with an alpha of 5%, a power of
90%, and a ratio of experimental trial participants to
control trial participants of 1:1.
In the 2009 EuroNeoNet report, the mortality among
extremely preterm infants was 33% and severe intracranial
haemorrhage was observed in 15%. In the SafeBoosC II
trial, the proportion of participants with the composite
primary outcome was approximately 34% in the control
group and 26% in the experimental group [27].
Based on the above, a total of 1600 infants would be
required to demonstrate a similar relative risk reduction
of 22%, with an alpha of 5%, and a power of 90%.
In SafeBoosC II, the intra-class correlation coefficient
(ICC) of the burden of hypoxia within pairs of twins was
negligible. The ICC for death before discharge and for
intraventricular haemorrhage grade 3 or 4 have previ-
ously been estimated to 0.00 (95% confidence interval
(CI) − 0.04 to 0.02) and − 0.01 (95% CI − 0.05 to 0.01)
[28]. These values correlate to a design effect very close
to 1 [28]. Based on this, we have not included twin ICC
in the sample size estimation.
Analysis of the primary outcome
The primary outcome analysis will be made on the
intention-to-treat population, and we will use mixed-
effect logistic regression. ‘Site’ will be included as a ran-
dom effect (intercept) and the remaining stratification
variables, age and intervention groups, will be included
as fixed effects. In addition, we will perform a range of
pre-defined sensitivity analyses to inform the interpret-
ation of the results of the primary analysis [23].
Safety
Predefined serious adverse reactions (SAR) will be re-
ported at 72 h after birth and serious adverse events
(SAE) will be reported at 36 weeks postmenstrual age.
Expedited reporting will not be used. An independent
data monitoring and safety committee is established to
monitor mortality, neonatal morbidity, and SARs with
‘certain’ or ‘probably/likely’ relationships with the cere-
bral NIRS oximeter and/or the application of the
evidence-based treatment guideline or any of its inter-
ventions. They include two neonatologists and a
biostatistician. The charter for the data monitoring and
safety committee has been written prior to the enrol-
ment of trial participants. The trial will not be stopped
early because of futility, and Lan-DeMets sequential
monitoring boundaries will be used at each interim ana-
lysis to assess if thresholds for statistical significance of
benefits or harms have been crossed [29]. Only one in-
terim analysis is planned, after one-third of trial partici-
pants have been randomised. Additional analyses will be
decided by the data monitoring and safety committee
members [23]. Based on primarily safety considerations,
the data monitoring and safety committee will make rec-
ommendations to the steering group to continue,
change, hold, or terminate the trial. The recommenda-
tions will be guided by the statistical monitoring guide-
lines, which is defined in the data monitoring and safety
committee charter (available from www.safeboosc.eu).
The preterm population is at high risk for SAEs and
most adverse events may be of a serious nature with or
without relevance to the SafeBoosC III trial intervention.
Both groups of the trial are expected to have a high pro-
portion of SAEs. It is therefore neither feasible nor
meaningful to record and report all adverse events.
Therefore, we have decided only to record and report
predefined SAEs and SARs. The SAEs include any event
of death, severe brain injury, necrotising enterocolitis,
bronchopulmonary dysplasia, retinopathy of prematurity,
or sepsis as defined under primary and exploratory out-
comes. These predefined SAEs have been chosen since
they cover the major neonatal morbidities seen in this
study population. The SARs are defined as any adverse
reaction related to the trial intervention that results in
death, is life-threatening, requires prolongation of exist-
ing hospitalisation, results in persistent or significant
disability or incapacity, or requires intervention to pre-
vent permanent impairment or damage. This includes
physical mishaps associated with managing the oximeter
and sensors, such as severe skin damage, critical dis-
placement of endotracheal tubes or endovascular lines,
and clinical mismanagement based on cerebral oximetry
monitoring data, such as interventions aiming at im-
proving cardiovascular status, respiratory status, and/or
oxygen transport.
Data management
All participants’ data are protected in accordance with
the Danish Act on the processing of personal data and
the Danish Health Act. The Copenhagen Trial Unit will
provide central, web-based data entry through an online
patient report form, in the open-source clinical trial soft-
ware OpenClinica®. This will handle the inclusion
procedure, the documentation of the stratification and
randomisation process, the SARs, and the relevant clin-
ical data from enrolled subjects, including primary and
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exploratory outcomes and explanatory variables. The
data will be entered into the online patient report form
directly by the medical staff. Forms for randomisation/
inclusion, end-of-monitoring at 72 h of age, and the 36-
week follow-up will be created. Data will be stored in ac-
cordance with guidelines issued by the Danish Data Pro-
tection Agency, from whom approval of the trial will be
sought. Only NICU numbers and study numbers will be
used to identify participants (i.e. the data kept at
Copenhagen Trial Unit is pseudo-anonymised), while
lists of study numbers and personal identifying informa-
tion (e.g. to allow Good Clinical Practice, data cleansing,
and later follow-up) will be kept at the NICUs. Six
months after the acceptance of the publication that pre-
sents the primary outcome, the dataset will be trans-
ferred to the Danish data archive. Before transfer,
subject study numbers will be removed, NICU numbers
will be replaced, sex documentation removed, and birth
weight and gestational age recoded into binary variables
to minimise the risk of re-identification. Use by other re-
searchers will depend on the permission of the steering
group.
The investigators permit trial-related monitoring,
audits, and regulatory inspections by providing direct
access to the source data and other relevant documents.
Trial data will be handled according to regulations of
data protection agencies in the respective countries.
Monitoring
Internal monitoring will be conducted by the Copenhagen
Trial Unit, who will monitor patient recruitment and
quality, completeness, and timeliness of data entry. In case
of problems, the principal investigator will be contacted.
External monitoring will be conducted by a Good
Clinical Practice person assigned by the principal investi-
gator at each site. The Good Clinical Practice person will
perform monitoring according to the monitoring plan,
which will is available at www.safeboosc.eu.
Ethical considerations
To obtain evidence-based knowledge on the potential
benefit and harms of NIRS-based cerebral monitoring in
the clinical management of premature infants, large-
scale randomised clinical trials are required. The Safe-
BoosC II trial served as a feasibility trial for the present
large-scale SafeBoosC III trial.
In most NICUs, there is still clinical equipoise regarding
the use of NIRS monitoring, meaning there is genuine un-
certainty over whether cerebral oximetry monitoring and
subsequent monitoring-based treatments are clinically
beneficial or harmful. Nevertheless, some NICUs have
started to use cerebral oxygenation monitoring as part of
routine clinical management. Thus, there might be a
limited time-window for this trial, since it may be more
difficult to test an intervention that is already in clinical
use [30]. Therefore, we aim at a pragmatic trial, rather
than doing a proof-of-concept trial first.
Extremely preterm infants demonstrate stress reac-
tions during routine manipulation. Positioning and re-
positioning of cerebral NIRS sensors can result in such
reactions. There are, however, no data to support sub-
stantially more risk or discomfort compared with no
intervention or compared with current routine care. All
interventions proposed in the evidence-based treatment
guideline are commonly used in this patient group [21].
‘Treatment as usual’, defined as treatment according
to participating hospital’s standard procedures, will be
provided to the control group. Also, this will be the care
provided to any participant that withdraws consent, in
addition to infants who are not included in the trial.
Multiple births will be randomised together and undergo
allocation to the same study group. This is to avoid par-
ents ascribing differences in their infants’ clinical courses
and outcomes based on group allocation resulting from
participation in this trial.
Publication plan
The trial protocol is registered at ClinicalTrials.gov
(NCT03770741) and all versions are available at www.
safeboosc.eu. Following trial completion, summary trial
data will additionally be entered at www.clinicaltrials.
gov. Further summary data of main outcomes will be en-
tered after statistical analyses are conducted. Attempts
will be made to publish all results, positive, neutral, as
well as negative, in a peer-reviewed international journal.
Authorship will be determined according to the Inter-
national Committee of Medical Journal Editors. An add-
itional requirement is one author per NICU completing
at least 30 participants. Ancillary studies with results po-
tentially affecting equipoise with regard to the value of
NIRS shall not be published before the main publication
of the SafeBoosC III trial. After the publication of trial
results, depersonalised individual patient data will be
uploaded at Zenodo.
Discussion
In this pragmatic trial, we plan to test the hypothesis
that the application of treatment based on cerebral NIRS
monitoring in extremely preterm infants will decrease a
composite outcome of either death or survival with se-
vere brain injury at 36 weeks postmenstrual age.
A Cochrane systematic review concluded that it is not
possible, based on the currently available literature, to
determine the specific benefits or harms of NIRS moni-
toring in extremely preterm infants [27]. The conclusion
of this review was that NIRS monitoring should only be
used in randomised clinical trials [31]. Despite this,
NIRS is routinely used in extremely preterm infants
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during the first days of life in numerous NICUs in mul-
tiple countries [32]. It is likely that this monitoring ap-
proach will become more common as evidence in other
patient groups becomes more convincing [33]. There-
fore, to prevent a non-evidence-based, large-scale clinical
uptake of NIRS monitoring, a robust randomised clinical
trial, such as the SafeBoosC III trial, is urgently required.
As described in the ‘Blinding’ section, it is not possible
to blind the clinical staff, the infants, and the parents
of infants participating in this trial. This circumstance
introduces risks of bias. Several previous studies have
shown that inadequate blinding of participants,
personnel, and outcome assessors in randomised trials
often results in overestimation of treatment effects for a
given intervention for all outcome types, including mor-
tality and subjective outcomes such as radiologic image
interpretation [34–37]. A meta-epidemiologic study
showed a high variability of treatment effect measured
on unblinded subjective outcomes, indicating that for
trials including subjective outcomes, the magnitude of
bias due to lack of blinding is unpredictable [34]. But
again, non-blinded trials compared to similar blinded tri-
als showed overestimation of intervention effects [30].
This meta-epidemiologic study included randomised tri-
als across all clinical fields. A meta-analysis, including
361 intensive-care randomised trials, evaluated the effect
of adequate blinding on effect estimates of mortality and
found no statistical significant difference between
blinded and unblinded trials, suggesting that there may
be little, if any, effect of adequate blinding on mortality
effect estimates in intensive care trials [38]. No meta-
epidemiologic studies, meta-analyses, or systematic re-
views have evaluated the effect of adequate/inadequate
blinding on intervention effects in neonatal randomised
trials. In conclusion, previous results suggest there is a
risk of biased results due to lack of blinding even on
mortality results. The design of the SafeBoosC III trial
strives to minimise the risks regarding the primary
outcome.
The pragmatic methodology of this trial also has some
limitations. Cranial ultrasound-based diagnoses will be
performed locally rather than centrally as was done in
SafeBoosC II [18]. This may potentially raise concerns in
SafeBoosC III since discrepancies between local readers
in different centres could be expected. However, when
comparing local and central interpretations of cranial
ultrasound images in preterm infants in previous clinical
trials, the sensitivity and specificity for local interpreta-
tions of severe brain injury were quite robust [39].
Furthermore, we have developed a web-based training
program for staff members caring for trial participants.
Among other topics, this web program includes a cranial
ultrasound module for the purpose of decreasing inter-
observer variability and heightening data quality.
As in all trial populations of extremely preterm infants,
a large number of participants will be twins, which can
cause statistical concerns arising from intra-class correl-
ation coefficients (ICC) [28]. We cannot with certainty
estimate the ICC for the composite outcome of death or
severe brain injury for the present trial. However, the
ICC of the burden of hypoxia within pairs of twins in
SafeBoosC II was negligible (ICC = 0.027) [27]. Addition-
ally, the twin ICC for pre-discharge death and grade III
or IV intraventricular haemorrhage has been estimated
in a previous study to 0.00 and − 0.01, which correlates
to a negligible design effect [28]. The details of how the
twin issue will be statistically accounted for is outlined
in the publication of the SafeBoosC III statistical and
data analysis plan [23].
The interventions in this trial are complex and rely on
a number of separate but interacting components, all
relevant for the potential success of the intervention.
When NIRS monitors show hypoxic values, neonatolo-
gists must evaluate the participant’s clinical status by
taking additional measures into consideration and decid-
ing on a possible modification of cardio-respiratory
support and interventions to increase blood oxygen
transport capacity, based on the treatment guideline.
This complexity will result in difficulty interpreting spe-
cific results, as it cannot be ascertained what exactly
causes a potential effect at 36 weeks postmenstrual age.
Furthermore, reproducing and generalising complex in-
terventions may be difficult for future clinicians asses-
sing the results of this trial [40]. However, since this is a
pragmatic effectiveness trial evaluating outcomes related
to NIRS-based cerebral oxygenation monitoring in rou-
tine practice and not the specific treatment choices per
se, this concern will not affect the purpose of the trial.
The Medical Research Council Framework has devel-
oped CONSORT guidelines in order to help trialists
develop clearly defined and reproducible complex inter-
ventions [41, 42]. We believe that the methodology in
the SafeBoosC III trial is in agreement with these guide-
lines, which is a major strength of this trial.
Obtaining prior informed consent from parents of crit-
ically ill neonates within the first hours following birth is
difficult and may challenge important standards of infor-
mation delivery, comprehension, competence, and vol-
untariness [43–45], and can also restrict the population
studied with the effect of impairing the generalisability
of results. Furthermore, since monitoring of cerebral
oxygenation has been used clinically for several years in
other patient groups, and now has entered neonatology
to a significant degree, the SafeBoosC III trial can be
considered comparative effectiveness research rather
than a test of an experimental intervention [46]. There-
fore, the protocol allows and encourages principal inves-
tigators at each NICU to consider and potentially to
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seek approval from research ethics boards for one of two
other consent forms, i.e. deferred informed consent [43]
and prior informed assent (opt-out with enrolment as
default) [47]. We believe this offers appropriate flexibility
in an international trial in an area where legitimate
ethical considerations are in conflict. For this purpose,
we have developed parental information sheets specific
for each consent method (Additional file 3).
Though extremely preterm infants constitute only
0.5% of all births [1], they represent an extremely high-
risk population, and thus their contribution to infant
mortality and to the prevalence of cerebral palsy exceeds
10% [48–50]. Accumulating evidence indicates that cere-
bral hypoxia is a significant cause of mortality as well as
brain injury in this population. Thus, monitoring of
cerebral oxygenation levels during the first days after
birth has the potential to address a significant health
problem. Although the overall risk in this population is
high, there are many other relevant contributing factors
to mortality and brain injury, and thus only a moderate
risk reduction can be expected. Therefore, a trial to
address this therapeutic question must be large in scope.
If the experimental intervention proves successful, we
may save 2000 extremely preterm infants or more every
year from death or a life with handicap due to brain in-
jury in high-income countries. The ensuing health eco-
nomics impact may thus be quite robust.
In conclusion, there is an urgent need for a rando-
mised clinical trial to assess the effects of cerebral NIRS
monitoring compared with treatment as usual in ex-
tremely preterm infants.
Trial status
The protocol is registered at www.clinicaltrials.gov
(NCT03770741; registered 10 December 2018). The first
infant was enrolled in June 2019 and the anticipated date
of study completion is October 2021. Recruitment status
can be accessed at www.safeboosc.eu.
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